UNASSIGNED: Medical records of patients who received treatment with sintilimab in combination with chemotherapy or chemotherapy alone as a second-line or beyond therapy were retrospectively analyzed. The study evaluated efficacy and safety. Indicators of efficacy included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Safety indicators included adverse events (AEs).
UNASSIGNED: This cohort comprised of 46 patients: 24 in the sintilimab combination chemotherapy group and 22 in the chemotherapy group. Chemotherapy received by both groups was either albumin-bound paclitaxel or irinotecan. Compared with the chemotherapy group, the sintilimab combination chemotherapy group had higher ORR and DCR (ORR: 37.5% vs. 9.1%, P=0.04; DCR: 75.0% vs. 40.9%, P=0.04), and significantly prolonged PFS and OS [median PFS (mPFS): 5.07 vs. 2.45 months, P=0.006; median OS (mOS): 14.43 vs. 10.34 months, P=0.009]. Also, there was no significant increase in the incidence of AEs in the sintilimab combination chemotherapy group, which was well tolerated by patients.
UNASSIGNED: Sintilimab in combination with chemotherapy is superior to single-agent chemotherapeutic treatment as second-line or later therapy in ES-SCLC patients who have not received prior immunotherapy. These results need to be confirmed in future clinical trials.
■回顾性分析接受sintilimab联合化疗或单独化疗作为二线或非二线治疗的患者的病历。该研究评估了疗效和安全性。疗效指标包括客观反应率(ORR),疾病控制率(DCR),无进展生存期(PFS),总生存率(OS)。安全性指标包括不良事件(AE)。
■该队列包括46名患者:sintilimab联合化疗组24名,化疗组22名。两组均接受白蛋白结合型紫杉醇或伊立替康的化疗。与化疗组相比,辛替利玛联合化疗组的ORR和DCR较高(ORR:37.5%vs.9.1%,P=0.04;DCR:75.0%vs.40.9%,P=0.04),显著延长PFS和OS[中位数PFS(mPFS):5.07vs.2.45个月,P=0.006;中位OS(mOS):14.43vs.10.34个月,P=0.009]。此外,sintilmab联合化疗组的AE发生率没有显著增加,患者耐受性良好。
■Sintilimab联合化疗在未接受过免疫治疗的ES-SCLC患者中作为二线或后期治疗优于单药化疗治疗。这些结果需要在未来的临床试验中得到证实。